What is Royalty Pharma's TEV-408 — total commitments?

Royalty Pharma (RPRX) reported TEV-408 — total commitments of $75M in Q2 2026.

What does TEV-408 — total commitments mean?

This metric represents the aggregate value of all contractual obligations to provide future funding for the acquisition of biopharmaceutical royalty interests. It reflects the total capital exposure the firm has committed to specific development-stage or commercial-stage assets. Monitoring this figure is essential for assessing the firm's long-term capital deployment strategy and future investment pipeline.

Royalty Pharma (RPRX) TEV-408 — Total Commitments

Screener

Other product segments

JNJ‑4804

$500M—

Litifilimab

$250M—

Similar metrics at other companies

ABRStructured Business — Total Commitments

$166.07M-34.7%

OTFTotal commitments

$6.7M-13.0%

USBTotal outstanding commitments

$873.32B+8.8%

USBTotal outstanding commitments

$873.32B+8.8%

KNTKMinimum Volume Commitments — Total revenues

$2M+567%

LENMultifamily — Total equity commitments

$2.2B0.0%

Other financials

Income statement

See full

Revenue$674.1M+16.5%

Operating income$133.1M-36.5%

Net income$17.9M-44.4%

EPS (diluted)$0.04-42.9%

Balance sheet

See full

Cash & equivalents$812.0M+28.5%

Total debt$9.0B+11.7%

Total equity$9.8B+3.1%

Total assets$19.8B+8.2%

Cash flow

See full

Operating cash flow$728.5M+100%

Valuation

See full

Market cap$25.6B+63.7%

Enterprise value$33.75B+46.5%

P/E31.4×+16.1×

P/S10.1×+3.3×

Profitability

See full

Operating margin59.6%-20.2pp

Net margin32.1%-12.3pp

Returns & leverage

See full

Return on equity8.5%-2.2pp

Debt / equity0.9×+0.1×

Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept rprx:ResearchAndDevelopmentCommitments.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 9:02 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001802768-26-000015

Product Candidates	Counterparties	Total Commitments	Funding Timing	Unfunded Commitments
JNJ‑4804	Johnson & Johnson	$500,000	Eight fixed quarterly payments commencing in the second quarter of 2026	$437,500
TEV-’408(1)	Teva Pharmaceuticals	75,000	Variable quarterly payments commencing in second quarter of 2026	65,149
Litifilimab	Biogen	250,000	Six fixed quarterly payments commencing in first quarter of 2025	—
Total		$825,000		$502,649

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Royalty Pharma's TEV-408 — total commitments?: Royalty Pharma (RPRX) reported TEV-408 — total commitments of $75M in Q2 2026.
What does TEV-408 — total commitments mean?: This metric represents the aggregate value of all contractual obligations to provide future funding for the acquisition of biopharmaceutical royalty interests. It reflects the total capital exposure the firm has committed to specific development-stage or commercial-stage assets. Monitoring this figure is essential for assessing the firm's long-term capital deployment strategy and future investment pipeline.